-1.06%
10.51%
8.67%
2.29%
54.03%
12.85%
-7.26%
AI Spotlight on MDWD
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration.It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd.was founded in 2000 and is headquartered in Yavne, Israel.
Market Data
| Last Price | 19.67 |
| Change Percentage | -1.06% |
| Open | 19.76 |
| Previous Close | 19.88 |
| Market Cap ( Millions) | 212 |
| Volume | 8325 |
| Year High | 24 |
| Year Low | 11.04 |
| M A 50 | 17.63 |
| M A 200 | 17.54 |
Financial Ratios
| FCF Yield | -9.80% |
| Dividend Yield | 0.00% |
| ROE | -104.99% |
| Debt / Equity | 18.87% |
| Net Debt / EBIDTA | -47.89% |
| Price To Book | 6.04 |
| Price Earnings Ratio | -7.37 |
| Price To FCF | -10.2 |
| Price To sales | 10.76 |
| EV / EBITDA | -16.21 |
News
- Nov -26 - MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript
- Nov -26 - MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
- Nov -26 - MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
- Oct -29 - MediWound Is A Healthy Investment
- Oct -10 - MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
- Aug -15 - MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
- Aug -14 - MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript
- Aug -14 - MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
- Aug -14 - MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
- Aug -07 - MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Aug -05 - MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
- Aug -02 - MediWound to Report Second Quarter 2024 Financial Results
- Jul -31 - Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?
- Jul -29 - MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
- Jul -16 - MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
- Jul -15 - Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
- Jul -15 - MediWound Announces $25 Million Strategic Private Placement Financing
- May -29 - MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript
- May -29 - MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
- May -29 - MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Bio-therapeutic, Non-surgical Solutions
Expected Growth : 10.2 %
What the company do ?
Bio-therapeutic, Non-surgical Solutions from MediWound Ltd. offer innovative, enzyme-based treatments for wound care, promoting efficient and effective healing.
Why we expect these perspectives ?
Increasing demand for non-invasive wound care solutions, growing prevalence of chronic wounds, and advancements in enzyme-based treatments drive the growth of MediWound's bio-therapeutic solutions.
Mediwound Ltd. Products
| Product Range | What is it ? |
|---|---|
| NexoBrid | A topical biological product for the treatment of severe burns, chronic wounds, and other complex wounds. |
| EscharEx | A topical biological product for the debridement of chronic and hard-to-heal wounds. |
| Curenity | A digital health platform for remote monitoring and management of wounds. |
MediWound Ltd.'s Porter Forces
Threat Of Substitutes
MediWound Ltd. has a moderate threat of substitutes due to the presence of alternative wound care products and treatments.
Bargaining Power Of Customers
MediWound Ltd.'s customers have limited bargaining power due to the company's specialized products and limited competition.
Bargaining Power Of Suppliers
MediWound Ltd. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and components.
Threat Of New Entrants
MediWound Ltd. faces a high threat of new entrants due to the growing demand for wound care products and the relatively low barriers to entry.
Intensity Of Rivalry
MediWound Ltd. operates in a moderately competitive industry with several established players, but the company's unique products and technology help to differentiate it from competitors.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 17.52% |
| Debt Cost | 6.19% |
| Equity Weight | 82.48% |
| Equity Cost | 8.01% |
| WACC | 7.69% |
| Leverage | 21.24% |
MediWound Ltd. : Quality Control
MediWound Ltd. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CGEN | Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of … |
| GLPG.AS | Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that … |
| HYL.BR | Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company … |
| BIOA-B.ST | BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials … |
| BSLN.SW | Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Galapagos
A-Score
1-Year Total Return ->
🥈
MediWound
A-Score
1-Year Total Return ->
🥉
Basilea Pharmaceutica
A-Score
1-Year Total Return ->
4
BioArctic
A-Score
1-Year Total Return ->
5
Compugen
A-Score
1-Year Total Return ->
6
